fig2

Figure 2. GSK-3β^S9A knock-in (βKI) preserves cardiac function and improves survival during aging. (A) Survival curves for WT mice (n = 21) and homozygous βKI mice (n = 20). Statistical analysis was conducted using the Gehan-Breslow-Wilcoxon test. ^#P < 0.05 βKI vs. WT. (B) LV ejection fraction (EF) in WT and homozygous βKI mice. *P < 0.05 vs. WT six months (WT6); ^#P < 0.05 vs. WT 24 months (WT24). (C) LV end-systolic (ES) elastance in WT and homozygous βKI. *P < 0.05 vs. WT6; ^#P < 0.05 vs. WT24. (D) LV chamber stiffness constant in WT and homozygous βKI. *P < 0.05 vs. WT6; ^#P < 0.05 vs. WT24. LV: Left ventricular; WT: wild type.